| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.MEHY.2016.04.039 |
| P8608 | Fatcat ID | release_77zsdixnwze5vflftfcriko2my |
| P932 | PMC publication ID | 4890167 |
| P698 | PubMed publication ID | 27241260 |
| P50 | author | Jack A Yanovski | Q30537295 |
| P2093 | author name string | Andrew P Demidowich | |
| Nicket Dedhia | |||
| Angela I Davis | |||
| P2860 | cites work | Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study | Q83915344 |
| Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children | Q84283220 | ||
| Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation | Q84573835 | ||
| Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study | Q87414232 | ||
| Long-term drug treatment for obesity: a systematic and clinical review | Q22253010 | ||
| Cidea is associated with lipid droplets and insulin sensitivity in humans | Q24317070 | ||
| The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation | Q24338420 | ||
| 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study | Q24633604 | ||
| The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes | Q26860579 | ||
| Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice | Q27323293 | ||
| Macrophage migration inhibitory factor deficiency ameliorates high-fat diet induced insulin resistance in mice with reduced adipose inflammation and hepatic steatosis | Q27324243 | ||
| Inflammation and metabolic disorders | Q27860923 | ||
| Obesity is associated with macrophage accumulation in adipose tissue | Q27860976 | ||
| Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance | Q28131660 | ||
| A role for mitochondria in NLRP3 inflammasome activation | Q28131794 | ||
| C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women | Q74845466 | ||
| Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects | Q79116989 | ||
| Gout-associated uric acid crystals activate the NALP3 inflammasome | Q28131797 | ||
| SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2 | Q28201656 | ||
| Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease | Q28220518 | ||
| Prevalence of overweight and obesity in the United States, 1999-2004 | Q28305811 | ||
| Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome | Q28586980 | ||
| Obesity induces a phenotypic switch in adipose tissue macrophage polarization | Q29547686 | ||
| MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity | Q29614283 | ||
| IKK-beta links inflammation to obesity-induced insulin resistance | Q29614285 | ||
| Inhibition of NF-kappa B by sodium salicylate and aspirin | Q29614708 | ||
| Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes | Q29615593 | ||
| NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals | Q29615704 | ||
| Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling | Q29616024 | ||
| The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance | Q29616026 | ||
| Interleukin-1-receptor antagonist in type 2 diabetes mellitus | Q29619001 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB | Q29619314 | ||
| A central role for JNK in obesity and insulin resistance | Q29619778 | ||
| Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death | Q29620021 | ||
| K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter | Q29620146 | ||
| CCR2 modulates inflammatory and metabolic effects of high-fat feeding | Q29622869 | ||
| Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling | Q30430981 | ||
| Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes | Q30548796 | ||
| Inflammation in atherosclerosis: from pathophysiology to practice | Q33709505 | ||
| TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome | Q34571799 | ||
| Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. | Q35043422 | ||
| The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial | Q35111527 | ||
| Inflammasome is a central player in the induction of obesity and insulin resistance | Q35216914 | ||
| Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage | Q35417136 | ||
| The IKK NF-kappa B system: a treasure trove for drug development | Q35621375 | ||
| Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes | Q36109128 | ||
| The inflammation highway: metabolism accelerates inflammatory traffic in obesity | Q36174974 | ||
| Mechanisms of beta-cell death in type 2 diabetes. | Q36321520 | ||
| Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. | Q36738131 | ||
| Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin | Q36804154 | ||
| The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity | Q36931760 | ||
| Markers of inflammation and fat distribution following weight loss in African-American and white women | Q36942949 | ||
| A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women | Q37022830 | ||
| Interleukin-18 and IL-18 binding protein | Q37220336 | ||
| Colchicine: its mechanism of action and efficacy in crystal-induced inflammation | Q37220559 | ||
| The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia | Q37325272 | ||
| Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide | Q37350905 | ||
| Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. | Q37466109 | ||
| Modes of action of aspirin-like drugs | Q37536125 | ||
| Oral colchicine (Colcrys): in the treatment and prophylaxis of gout | Q37778056 | ||
| A clinical perspective of IL-1β as the gatekeeper of inflammation | Q37869439 | ||
| Islet amyloid polypeptide, islet amyloid, and diabetes mellitus | Q37899668 | ||
| Cross-regulation between the IL-1β/IL-18 processing inflammasome and other inflammatory cytokines | Q37916934 | ||
| Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes | Q38245095 | ||
| Interleukin-6 depletion selectively improves hepatic insulin action in obesity | Q38327645 | ||
| Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout | Q39574591 | ||
| Colchicine for recurrent pericarditis (CORP): a randomized trial. | Q39996422 | ||
| The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial Mediterranean fever | Q40298767 | ||
| Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis | Q40368112 | ||
| Chronic colchicine treatment does not impair glucose tolerance in familial Mediterranean fever patients | Q40658562 | ||
| Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. | Q40701074 | ||
| Long-term colchicine treatment in children with familial mediterranean fever | Q40746167 | ||
| Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. | Q42271438 | ||
| Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. | Q42465022 | ||
| Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity | Q42703006 | ||
| XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model | Q43120718 | ||
| Interleukin-18 increases TLR4 and mannose receptor expression and modulates cytokine production in human monocytes | Q43214205 | ||
| Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial | Q45369180 | ||
| Adipose inflammation in obesity: relationship with circulating levels of inflammatory markers and association with surgery-induced weight loss. | Q46021801 | ||
| Low-dose colchicine for secondary prevention of cardiovascular disease | Q46245044 | ||
| Successful multi-intervention treatment of severe obesity: a 7-year prospective study with 96% follow-up | Q46364643 | ||
| High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children | Q46672449 | ||
| Long-term weight regain after gastric bypass: a 5-year prospective study | Q47238719 | ||
| The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? | Q47288086 | ||
| Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects | Q47402001 | ||
| Differential expression of NLRP3 among hematopoietic cells. | Q50528108 | ||
| Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. | Q51355147 | ||
| Metabolic, inflammatory, endothelial and haemostatic markers in a group of Italian obese children and adolescents. | Q51382505 | ||
| Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. | Q51580928 | ||
| Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. | Q53620233 | ||
| Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991 | Q57196041 | ||
| Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew–Paisley study) | Q57396321 | ||
| Elevated C-reactive protein levels in overweight and obese adults | Q57830181 | ||
| Increased Inflammatory Properties of Adipose Tissue Macrophages Recruited During Diet-Induced Obesity | Q58197140 | ||
| Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic Patients | Q61669062 | ||
| Obesity and Inflammation: Change in Adiponectin, C-Reactive Protein, Tumour Necrosis Factor-Alpha and Interleukin-6 After Bariatric Surgery | Q62090496 | ||
| Long-term colchicine prophylaxis in familial Mediterranean fever | Q67692370 | ||
| Colchicine in the treatment of the cutaneous manifestations of Behçet's disease | Q71468179 | ||
| The relation of body fat mass and distribution to markers of chronic inflammation | Q74845460 | ||
| P921 | main subject | (S)-(−)-colchicine | Q326224 |
| P304 | page(s) | 67-73 | |
| P577 | publication date | 2016-04-25 | |
| P1433 | published in | Medical Hypotheses | Q5558534 |
| P1476 | title | Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation | |
| P478 | volume | 92 |
| Q39051784 | Anti-inflammatory drugs as promising cardiovascular treatments. |
| Q92351085 | Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial |
| Q48214593 | Inflammasomes in Mycobacterium tuberculosis-Driven Immunity |
| Q92256742 | Inflammation as a Therapeutic Target in Atherosclerosis |
| Q101452721 | Membrane nanotubes facilitate the propagation of inflammatory injury in the heart upon overactivation of the β-adrenergic receptor |
| Q47248842 | Novel insights in the metabolic syndrome-induced oxidative stress and inflammation-mediated atherosclerosis |
| Q61807037 | Paclitaxel Enhances the Innate Immunity by Promoting NLRP3 Inflammasome Activation in Macrophages |
| Q95627597 | Review of trials currently testing treatment and prevention of COVID-19 |
| Q97519191 | Severe COVID-19: NLRP3 Inflammasome Dysregulated |
| Q39235242 | Upstream biomanufacturing of pharmaceutical colchicine |
Search more.